Dr. Bob Miller Functional Genomics Testing Program

I. Nature and Positioning of the Testing

This program utilizes functional gene testing, which is fundamentally different from traditional whole genome sequencing.

The drawbacks of Whole Genome Sequencing (WGS) include its massive data volume and complex analysis. The functions of many variants remain unclear, making precise interpretation difficult and challenging to apply directly for health guidance. It essentially provides a comprehensive listing of DNA sequence arrangements.

In stark contrast, this testing is the opposite: 'Functional gene testing involves the targeted detection of a small subset of genes related to specific functions (such as metabolism, nutrition, drug response, disease risk, etc.)'. It precisely focuses on health issues, identifying one's genetic, metabolic, chronic disease, and anti-aging weaknesses to provide direct intervention and impact.

It 'directly tests known functional genes, rapidly delivers results, and provides improvement recommendations', rather than merely listing data.

II. Specific Scope of Genes Tested

The testing focuses on core genetic loci closely related to specific physiological functions in the human body, covering:

• Genes related to metabolic pathways (e.g., glucose metabolism, lipid metabolism, folate metabolism)
• Genes related to drug metabolism (e.g., CYP450 family)
• Genes related to nutrient absorption and utilization (e.g., MTHFR, VDR, TCFTL2)
• Genes related to disease susceptibility (e.g., APOE, BRCA1/2, ICAM1)

A total of 260,000 genetic loci, divided into 7 levels and 30 modules.

III. Core Technology Chip and Detection Capability

Utilizes the 'exclusively customized gene testing chip designed by Dr. Bob Miller for the pyramid structure, which has been patented.'

This chip can detect exclusive proprietary SNPs gene targets that have a significant impact on human function (the core of 30 years of research), helping doctors trace the genetic root causes of individual chronic diseases within metabolic pathways.

IV. Core International Patents

Authorized international patent numbers: 7,332,273, 7,790,389, 8,114,584, 8,273,304, 8,501,122

V. National-Level Testing Laboratory

Lingtu International Medical Research and Beijing Bioelectron Boao Yihe Zekang established a joint testing platform laboratory for the Dr. Bob Miller project.

On September 9, 2024, Lingtu signed an agreement with Beijing Bioelectron Boao Yihe Zekang Technology Co., Ltd. to establish a joint laboratory. All sample processing and testing services within China are provided by Beijing Bioelectron Boao Jingdian.

Bioelectron Boao was co-founded with the participation of Academician Cheng Jing from Tsinghua University, relying on Tsinghua University and jointly registered with Huazhong University of Science and Technology, Chinese Academy of Medical Sciences, and Academy of Military Medical Sciences.

Laboratory accreditations: CNAS L2451, ISO14001, ISO27001 certifications.

VI. Scientific Research and Standard-Setting Achievements

• Cumulative authorized patents at home and abroad exceed 700, with a patent conversion rate over 50%
• Awarded the National Technology Invention Award twice, and the National Science and Technology Progress Award in 2023
• Led the formulation of 17 national standards, 9 industry standards, and 2 group standards